Literature DB >> 12401522

Engagement of the NG2 proteoglycan triggers cell spreading via rac and p130cas.

Mousumi Majumdar1, Kristiina Vuori, William B Stallcup.   

Abstract

Cells that express the NG2 proteoglycan will spread on surfaces coated with monoclonal antibodies against this membrane-spanning protein. On surfaces coated with the N143 monoclonal antibody, this cell spreading occurs by extension of lamellipodia, suggesting that activation of the small GTPase rac is involved in the observed morphological change. Support for this hypothesis comes from the finding of increased levels of GTP-bound rac in cells spreading on N143-coated surfaces. Furthermore, lamellipodia extension is blocked by transfection of cells with the dominant negative rac construct N17rac, but not by transfection with N17cdc42. Formation of lamellipodia on the N143-coated surfaces is also inhibited by transfection of the dominant negative CasdeltaSD construct. This result implicates p130cas as an additional functional player in NG2-mediated cell spreading. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12401522     DOI: 10.1016/s0898-6568(02)00045-1

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  19 in total

Review 1.  CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.

Authors:  Matthew A Price; Leah E Colvin Wanshura; Jianbo Yang; Jennifer Carlson; Bo Xiang; Guiyuan Li; Soldano Ferrone; Arkadiusz Z Dudek; Eva A Turley; James B McCarthy
Journal:  Pigment Cell Melanoma Res       Date:  2011-12       Impact factor: 4.693

2.  Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan.

Authors:  Ugur Ozerdem; William B Stallcup
Journal:  Angiogenesis       Date:  2004       Impact factor: 9.596

Review 3.  NG2-expressing cells in the nervous system: role of the proteoglycan in migration and glial-neuron interaction.

Authors:  Khalad Karram; Nivedita Chatterjee; Jacqueline Trotter
Journal:  J Anat       Date:  2005-12       Impact factor: 2.610

4.  Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.

Authors:  Jianbo Yang; Matthew A Price; Leah E C Wanshura; Jinsong He; Mei Yi; Danny R Welch; Guiyuan Li; Sean Conner; Jonathan Sachs; Eva A Turley; James B McCarthy
Journal:  Melanoma Res       Date:  2019-08       Impact factor: 3.599

Review 5.  Transduction of extracellular cues into cell polarity: the role of the transmembrane proteoglycan NG2.

Authors:  Fabien Binamé
Journal:  Mol Neurobiol       Date:  2014-01-05       Impact factor: 5.590

Review 6.  Antithetic roles of proteoglycans in cancer.

Authors:  Elena Garusi; Silvia Rossi; Roberto Perris
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

Review 7.  Regulation of oligodendrocyte precursor migration during development, in adulthood and in pathology.

Authors:  Fernando de Castro; Ana Bribián; Maria Cristina Ortega
Journal:  Cell Mol Life Sci       Date:  2013-05-21       Impact factor: 9.261

Review 8.  A role for the NG2 proteoglycan in glioma progression.

Authors:  William B Stallcup; Feng-Ju Huang
Journal:  Cell Adh Migr       Date:  2008-07-13       Impact factor: 3.405

9.  Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.

Authors:  Jianbo Yang; Matthew A Price; Gui Yuan Li; Menashe Bar-Eli; Ravi Salgia; Ramasamy Jagedeeswaran; Jennifer H Carlson; Soldano Ferrone; Eva A Turley; James B McCarthy
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

10.  NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion.

Authors:  Sabrina Cattaruzza; Pier Andrea Nicolosi; Paola Braghetta; Laura Pazzaglia; Maria Serena Benassi; Piero Picci; Katia Lacrima; Daniela Zanocco; Erika Rizzo; William B Stallcup; Alfonso Colombatti; Roberto Perris
Journal:  J Mol Cell Biol       Date:  2013-04-03       Impact factor: 6.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.